Sector revisions Pacira BioSciences, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 01:00:02 2025-12-05 pm EST			5-day change	1st Jan Change
24.11 ^USD	+0.54%		+2.76%	+28.56%

Dec. 03	Pacira Biosciences reports inducement grants under Nasdaq Listing Rule	RE
Dec. 02	Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain	MT

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	PACIRA BIOSCIENCES, INC.							6
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							24
	ABBVIE INC.							29
	ROCHE HOLDING AG							18
	ASTRAZENECA PLC							19
	NOVARTIS AG							19
	MERCK & CO., INC.							26
	NOVO NORDISK A/S							20
	AMGEN INC.							27
	GILEAD SCIENCES, INC.							25
	PFIZER INC.							24
	SANOFI							22
	VERTEX PHARMACEUTICALS INCORPORATED							25
	BRISTOL-MYERS SQUIBB COMPANY							22
	GSK PLC							18
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	ALNYLAM PHARMACEUTICALS, INC.							24
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							18
	Average							21
	Weighted average by Cap.							24